Separately, ValuEngine downgraded Vermillion from a hold rating to a sell rating in a research report on Friday, July 28th.
Shares of Vermillion (NASDAQ:VRML) opened at $1.74 on Thursday. The company has a quick ratio of 3.16, a current ratio of 3.21 and a debt-to-equity ratio of 0.34. Vermillion has a fifty-two week low of $0.76 and a fifty-two week high of $2.85.
Vermillion (NASDAQ:VRML) last posted its earnings results on Wednesday, August 9th. The company reported ($0.04) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The company had revenue of $0.90 million during the quarter. Vermillion had a negative return on equity of 215.26% and a negative net margin of 372.05%.
Hedge funds have recently added to or reduced their stakes in the business. Essex Investment Management Co. LLC boosted its holdings in Vermillion by 145.8% during the third quarter. Essex Investment Management Co. LLC now owns 216,607 shares of the company’s stock valued at $390,000 after acquiring an additional 128,494 shares during the period. Vanguard Group Inc. raised its position in Vermillion by 0.7% in the second quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock worth $1,068,000 after purchasing an additional 4,200 shares in the last quarter. Finally, Birchview Capital LP raised its position in Vermillion by 7.9% in the third quarter. Birchview Capital LP now owns 2,462,933 shares of the company’s stock worth $4,433,000 after purchasing an additional 180,000 shares in the last quarter. Institutional investors own 33.49% of the company’s stock.
Vermillion Company Profile
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with our FREE daily email newsletter.